Telomir Pharmaceuticals (TELO) said Wednesday that preclinical findings showed that Telomir-1 reduces tumor size by 50% in a prostate cancer animal model using "highly aggressive" human prostate cancer cells.
Telomir-1 "actively suppresses cancer growth rather than promoting it, and protects against chemotherapy-induced toxicity and mortality when combined with Paclitaxel," a chemotherapy drug that is often linked with severe toxicity and side effects, the company said.
Telomir said it is advancing Telomir-1 in several indications in addition to oncology. Studies are assessing the drug in age-related diseases like age-related macular degeneration and Wilson's disease, the company said.
The company said it plans to file an investigational new drug application by the end of the year.
Telomir shares were up 4% in recent Wednesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。